A Phase 2 interventional study of Oxaliplatin and Chemoradiation in Rectal Cancer, sponsored by Oslo University Hospital. Completed at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-29.
Sponsored by Oslo University Hospital · Phase 2, Interventional, and Treatment
Oxaliplatin and 5FU based preoperative chemoradiation in rectal cancer.
Effect of treatment, safety profile and quality of life scorings.
1,762 studies on the registry are indexed under Rectal Neoplasms; 518 are open to participants now.
This study's enrollment of 109 is above the median of 65 across 1,298 interventional studies indexed under Rectal Neoplasms.
Browse Rectal Neoplasms studies →Oslo University Hospital is the lead sponsor of 810 studies on the registry; 148 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Rectal cancer
Neoadjuvant chemotherapy and chemoradiation
Drug: Oxaliplatin · Drug: Chemoradiation · Drug: 5-FU · Radiation: Preoperative chemoradiation · Procedure: Pelvic surgery · Drug: Neoadjuvant oxaliplatin
Safety profile
Time frame: 5 years
Number of patients obtaining pCR
Time frame: 5 years
Clinical, radiological and molecular response to treatment
Time frame: 5 years
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oslo University Hospital